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Treatment-associated change in apelin concentration in patients with 
hypertension and its relationship with left ventricular diastolic function
Introduction
Apelin is an endogenous peptide first isolated from bovine stom-
ach extracts, and is reported to have a variety of functions in the 
cardiovascular system. Apelin has been identified as endogenous 
ligand for the G-protein coupled receptor apelin receptor (APJ), 
which has structural similarities with the angiotensin II type 1 re-
ceptor (1, 2). It has been shown that the apelin/APJ system plays a 
role in the pathophysiology of atherosclerosis, coronary artery dis-
ease, heart failure, hypertension, and pulmonary hypertension (3). 
It has been reported that plasma apelin concentration is decreased 
in patients with hypertension (4, 5). The apelin/APJ pathway influ-
ences blood pressure by an endothelium-dependent, nitric oxide 
(NO)-mediated mechanism that causes arterial vasodilatation (6).
The relationship between apelin concentration and left ven-
tricular (LV) diastolic function in patients with essential hyper-
tension is not completely understood, although recently it has 
been reported that circulating apelin concentration is associ-
ated with LV systolic and diastolic impairment (5).
We hypothesized that plasma apelin concentration would be 
lower in patients with untreated arterial hypertension than pa-
tients with normal blood pressure and that apelin concentration 
would rise in response to effective treatment of hypertension 
independent of the drug choice. We also sought to examine the 
relationship between apelin concentration and LV diastolic func-
tion before and after treatment.
In order to achieve these goals, we 1) compared the plasma 
apelin concentration of patients with hypertension and healthy 
controls; 2) examined the change in plasma apelin concentration 
in patients with newly diagnosed hypertension after 1 month of 
drug therapy, and compared the effect of two anti-hypertensive 
drug regimens on apelin concentration (telmisartan or amlodip-
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ine); and 3) examined the relationship between plasma apelin 
concentration and improvements in LV diastolic function after 1 
month of treatment.
Methods
Patients
We prospectively enrolled 90 patients (50 men and 40 wom-
en), aged over 18 years referred to our outpatient cardiology clin-
ic and diagnosed with stage 1 or 2 essential hypertension based 
on the European Society of Cardiology guidelines (7). Thirty-three 
age- and sex-matched participants with normal blood pressure 
who were admitted to our outpatient cardiology clinic with atypi-
cal chest pain or palpitation served as the control group. The 
local Ethics Committee approved the study protocol, and writ-
ten informed consent was obtained from each participant. At the 
first visit, each patient underwent a medical evaluation, includ-
ing clinical history, physical examination, routine blood analysis, 
lipid profile, electrocardiography, and echocardiography. Blood 
pressure was measured with an appropriately sized arm cuff and 
a manual mercury sphygmomanometer after 5 minutes of rest. 
The same physician performed all measurements, and the mean 
of two sitting measurements at 2-minute intervals was used. Hy-
pertension was defined as a systolic blood pressure (SBP) ≥140 
mm Hg and/or a diastolic blood pressure (DBP) ≥90 mm Hg on 
repeated measurements. Apelin concentration has been shown 
to be associated with several conditions, including coronary ar-
tery stenosis, diabetes, obesity, aortic stenosis, chronic kidney 
disease, and heart failure (8–13). Therefore, patients who had a 
history of coronary artery disease, secondary hypertension, dia-
betes mellitus, moderate or severe valvular heart disease, body 
mass index above 30 kg/m2, LV ejection fraction <45%, or serum 
creatinine concentration >1.6 mg/dL were excluded. None of the 
patients were taking any antihypertensive medication at base-
line. Patients diagnosed with essential hypertension were ran-
domly assigned to treatment with either 80 mg telmisartan or 10 
mg amlodipine orally once daily. Randomization was performed 
using a random number table. In addition to routine blood analy-
sis, another blood sample for apelin measurement was obtained 
from each patient and stored in our laboratory for later analysis. 
Thirteen patients were excluded from the final analysis: five 
were lost to follow-up (three in the amlodipine group and two in 
the telmisartan group); five stopped treatment due to side effects 
(three in the amlodipine group and two in the telmisartan group); 
and three required additional drug therapy to bring blood pres-
sure under control (one in the amlodipine group and two in the 
telmisartan group).
After 1 month of treatment, patients with hypertension were 
recalled for echocardiography and blood sampling for measure-
ment of follow-up plasma apelin concentration. Ambulatory 
blood pressure monitoring was performed to evaluate the ef-
fectiveness of antihypertensive therapy using an oscillometric 
device (Tracker NIBP2, DelMar Reynolds Medical, Morrisville, 
USA) that recorded blood pressure every 30 minutes during the 
day and every 45 minutes at night.
Blood biochemistry and measurement 
of plasma apelin concentration
All blood samples were taken in the morning after 12 hours 
of fasting. Complete blood count, blood glucose levels, lipid pro-
file, liver enzyme, and creatinine concentrations were analyzed 
on the same day. For apelin analysis, blood samples were im-
mediately centrifuged, and plasma was separated and stored at 
–80°C for analysis as a batch after randomization. Plasma apelin 
concentration was quantified by enzyme-linked immunosorbent 
assay (Human apelin-12 EIA Kit, Phoenix Pharmaceuticals, USA), 
with a minimum detectable concentration of 0.07 ng/mL, intra-
assay variation of ±10% and inter-assay variation of ±15%.
Echocardiography
Echocardiographic imaging was performed using Philips So-
nos 7500 Ultrasound System equipment with a 2–4-MHz multifre-
quency transducer (Andover, MA, USA). The same experienced 
echocardiographer performed all the studies with the patients in 
left lateral decubitus position. Cardiac chamber dimensions and 
wall thicknesses were measured from parasternal long-axis and 
apical four-chamber views according to the American Society of 
Echocardiography guidelines (14). Left atrial (LA) volumes were 
measured from the apical four-chamber view using the biplane 
area-length method, and indexed for body surface area. Left 
ventricular end-systolic and end-diastolic volumes, and ejection 
fraction, were estimated using a modified Simpson’s biplane 
method. Left ventricular mass (LVM) was calculated according 
to the Devereux formula, and corrected for body surface area to 
determine the LVM index (LVMI).
Transmitral pulsed Doppler was recorded from the apical 
four-chamber view, with the sample volume positioned at the 
tips of the mitral valve leaflets. Peak early filling (E) and atrial 
filling (A) velocities, the deceleration time of the peak E wave 
(MDT), the duration of the mitral A wave (A time), and isovolumic 
relaxation time (IVRT) were measured from the transmitral flow 
pattern, and the E/A ratio was calculated.
Pulsed-wave tissue Doppler imaging was performed on the 
lateral and septal sites of the mitral annulus from the apical four-
chamber view. Mean values of three consecutive beats were 
used for analysis. Peak systolic myocardial velocity (s), and peak 
early and late diastolic velocities (e’ and a’), were measured. 
Mean values of the tissue Doppler measurements from the lat-
eral and septal sites were calculated. The ratio of mitral inflow 
early diastolic velocity to mitral annular peak early diastolic ve-
locity (E/e’) was calculated.
The myocardial performance index (MPI, also known as the 
Tei-Doppler index), an index of combined systolic and diastolic 
function, was defined as the sum of the isovolumic contraction 
time and the isovolumic relaxation time divided by the ejection 
time (15). The MPI for the LV was calculated from the pulsed-
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wave tissue Doppler recordings on the lateral (lateral MPI) and 
septal (septal MPI) sites of the mitral annulus from the apical 
four-chamber view.
Statistical analysis
The frequency (percent) of categorical variables, and 
mean±standard deviation for continuous variables are pre-
sented as descriptive statistics. The nature of the distribution of 
continuous variables was evaluated using the Shapiro-Wilk test. 
The chi-squared test and Kruskal-Wallis variance analysis were 
used to compare more than two independent groups for cat-
egorical variables and continuous variables, respectively. Bon-
ferroni corrected Mann-Whitney U test was used after Kruskal-
Wallis variance analysis in the case of significant differences 
between groups. The paired t-tests were performed to compare 
two dependent groups. In the presence of covariates, covari-
ance analysis was undertaken to compare independent groups 
for continuous variables. The Spearman correlation coefficient 
was used to assess the degree of association between two vari-
ables. All statistical analyses were performed using SPSS 17.0 
software program (SPSS Inc., Chicago, IL, USA). A p value <0.05 
was considered statistically significant.
Results
Data obtained from 77 patients (of median age 48 years, 
44 of whom were men) with hypertension and 33 controls (21 
men, median age: 49 years) were analyzed. Thirty-eight pa-
tients were randomized to treatment with amlodipine, and 39 
to treatment with telmisartan. The demographic and clinical 
characteristics of the study population at baseline were similar 
between control and treatment groups except blood pressure 
measurements which were lower in the control group (Table 
1). Baseline mean apelin concentration and hemoglobin level 
was significantly higher in the control group than the treatment 
groups (Table 1).
Baseline echocardiographic parameters are shown in Table 
2. The LVMI, interventricular septum thickness, and posterior 
wall thickness were similar between the telmisartan and am-
lodipine groups at baseline, and were significantly higher than 
the control group (Table 2). Left ventricular end-diastolic diam-
eter was higher in the control group than the treatment groups, 
whereas EF was similar among 3 groups. The mean lateral and 
septal annular peak early diastolic velocities (lat-sep e’) at base-
line were 8.9±1.8 cm/s and 8.3±2.3 cm/s in the telmisartan and 
amlodipine groups, respectively (p=0.239). Indices of LV diastolic 
function before treatment were similar between the telmisartan 
and amlodipine groups (Table 2).
The mean plasma apelin concentration before treatment in 
the telmisartan, amlodipine, and control groups was 0.27±0.13 
ng/mL, 0.32±0.17 ng/mL, and 0.56±0.17 ng/mL, respectively 
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Table 1. Demographic, clinical and laboratory characteristics of 
telmisartan and amlodipine groups at baseline
  Telmisartan  Amlodipine Control P 
  group (n=39) group (n=38) group (n=33)
Age, years 48±11 48±9 49±5 0.735
Female, n,% 17 (43) 16 (42) 12 (36) 0.810
Height, cm 170±9 170±9 165±5 0.078
Weight, kg 75±12 78±11 72±5 0.089
BMI, kg/m2 25.9±2.4 26.8±2.1 26.4±1.5 0.175
Glucose, mg/dL 95±7 93±6 92±4 0.182
HDL, mg/dL 46±11 49±18 40±8 0.163
LDL, mg/dL 145±41 130±42  134±25 0.227
Triglyceride, mg/dL 126±32 131±34 118±27 0.342
Creatinine, mg/dL 0.7±0.1 0.7±0.1 0.7±0.1 0.333
Hemoglobin, mg/dL 14.4±1.3 15.0±1.4  15.8±1.3 0.0011
Apelin, ng/mL 0.27±0.13 0.32±0.17 0.56±0.17 <0.0011
SBP, mm Hg 154±7 154±10 118±7 <0.0011
DBP, mm Hg 92±6 95±9  78±4 <0.0011
Values are expressed as mean±standard deviation. BMI - body mass index; BSA - 
body surface area; DBP - diastolic blood pressure; HDL - high-density lipoprotein; 
LDL - low-density lipoprotein; SBP - systolic blood pressure. 1- Significant difference 
between control-amlodipine and control-telmisartan groups
Table 2. Echocardiographic parameters of study groups at baseline
  Telmisartan  Amlodipine Control P 
  group (n=39) group (n=38) group (n=33)
Left atrial size, cm 3.4±0.2 3.5±0.2 3.4±0.2 0.251
LV end-diastolic 
dimension, cm 4.3±0.3 4.3±0.5 4.6±0.4 0.0031
IST, cm 1.1±0.1 1.1±0.1 0.8±0.1 <0.0011
PWT, cm 1.1±0.1 1.0±0.1  0.8±0.1 <0.0011
LVEF, % 60±3 60±2 64±4 0.252
E/A ratio 1.0±0.3 0.9±0.2 0.9±0.3 0.289
IVRT, ms 98±14 101±12  84±6 <0.0011
Lat-sep e’, cm/s 8.9±1.8 8.3±2.3 12.6±1.5 <0.0011
Lateral IVRT, ms 96±11 99±9 86±5 <0.0011
Septal IVRT, ms 95±9 100±12 85±7 <0.0011
Lateral s’, cm/s 11.5±0.6 11.1±0.8 12.7±0.5 0.189
Septal s’, cm/s 10.9±0.6  10.8±0.7 11.5±0.6 0.354
E/e’ ratio 7.8±1.5 8.6±2.2 5.2±0.9 <0.0011
LAVI, mL/ m2 21.0±3.6 21.1±3.0 20.0±2.1 0.283
Lateral MPI 0.64±0.16 0.64±0.11 0.41±0.05 <0.0011
Septal MPI 0.61±0.10 0.63±0.08 0.41±0.05 <0.0011
LVMI, gr/ m2 114±23 112±24 97±13 <0.0011
Values are expressed as mean±standard deviation. A - peak atrial filling velocity; E - 
peak early filling velocity; IST - interventricular septum thickness; IVRT - isovolumic 
relaxation time; Lat/sep e’ - mean of lateral and septal peak early diastolic velocities; 
LAVI - left atrial volume index; LV - left ventricle; LVEF - LV ejection fraction; LVMI - LV 
mass index; MPI - myocardial performance index; s’ - peak systolic annular velocity; 
PWT - Posterior wall thickness. 1- Significant difference between control-amlodipine 
and control-telmisartan groups
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(p<0.001). Apelin concentrations were similar between treat-
ment groups (p=0.150). Apelin concentration was significantly 
increased in whole patients taking antihypertensive therapy 
(from 0.29±0.15 ng/mL at baseline to 0.36±0.17 ng/mL at 1 month, 
p<0.001). There was also a significant increase in plasma ape-
lin concentration after 1 month of treatment in both the amlo-
dipine (from 0.32±0.17 ng/mL at baseline to 0.38±0.17 ng/mL at 
1 month, p=0.013) and telmisartan groups (from 0.27±0.13 ng/
mL at baseline to 0.34±0.18 ng/mL at 1 month, p=0.009). The in-
cremental change was similar in each of the treatment groups 
(p=0.922, Fig. 1 and Table 3).
After 1 month of treatment, significant reductions in SBP 
and DBP were observed in patients with hypertension (p<0.001 
for both); the extent of the reduction was similar for both in 
each of the treatment groups (p=0.658 for SBP and p=0.271 for 
DBP, Table 3).
Changes in diastolic function after treatment are presented 
in Table 4: there were significant improvements in IVRT, lat-sep 
e’, lateral IVRT, septal IVRT, E/e’, left atrial volume index, lateral 
MPI and septal MPI in both treatment groups, and the extent 
of the improvements were similar in each of the groups. The 
proportional change in plasma apelin concentration after an-
tihypertensive therapy was not significantly associated with 
the proportional change in blood pressure or diastolic indices, 
except lateral MPI (Table 5).
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Figure 1. Effects of a month of treatment with amlodipine or telmisartan 
on plasma apelin levels. Data are shown as means
Table 3. Comparison of apelin concentration, systolic and diastolic 
blood pressures before and after treatment
  Group Baseline After P* P** 
   treatment
Apelin, ng/mL Telmisartan 0.27±0.13 0.34±0.18 0.009 
0.922
  Amlodipine 0.32±0.17 0.38±0.17 0.013
SBP, mm Hg Telmisartan 154±7 122±8 <0.001 
0.658
  Amlodipine 154±10 123±10 <0.001
DBP, mm Hg Telmisartan 92±6 74±9 <0.001 
0.271
  Amlodipine  95±9 76±8 <0.001
Values are expressed as mean±standard deviation. DBP - diastolic blood pressure; 
SBP - systolic blood pressure. *P value of paired samples test; **P value of compari-
son of groups in terms of after treatment values corrected for baseline values
Table 4. Echocardiographic indices for the assessment of diastolic function before and after treatment
   Telmisartan group   Amlodipine group
  Baseline After P* Baseline After P* P** 
   treatment   treatment
E wave, cm/s 68±12 67±11 0.326 68±14 66±13 0.344 0.795
A wave, cm/s 72±16 69±13 0.070 78±13 69±13 <0.001 0.057
MDT, ms 226±25 221±16 0.122 227±20 222±25 0.217 0.922
IVRT, ms 98±14 89±10 <0.001 101±12 91±10 <0.001 0.773
E/A ratio 1.00±0.31 0.99±0.23 0.959 0.89±0.25 0.99±0.30 0.006 0.110
Lat-sep e’, cm/s 8.9±1.8 10.7±1.8 <0.001 8.3±2.3 10.0±2.6 <0.001 0.564
Lateral IVRT, ms 96±11 90±9 <0.001 99±9 91±10 <0.001 0.692
Septal IVRT, ms 95±9 88±7 <0.001 100±12 90±7 <0.001 0.785
Lateral s’, cm/s 11.5±0.5 11.8±0.6 0.286 11.1±0.8 11.6±0.7 0.156 0.324
Septal s’, cm/s 10.9±0.6 11.3±0.5 0.212 10.8±0.7 11.1±0.7 0.243 0.355
E/e’ ratio 7.8±1.5 6.3±1.1 <0.001 8.6±2.2 6.9±1.9 <0.001 0.516
LAVI, mL/m2 21.0±3.6 18.9±2.7 <0.001 21.1±3.0 19.0±2.7 <0.001 0.959
Lateral MPI 0.64±0.16 0.61±0.23 0.021 0.64±0.11 0.58±0.07 <0.001 0.270
Septal MPI 0.61±0.10 0.58±0.08 0.006 0.63±0.08 0.59±0.07 <0.001 0.837
Values are expressed as mean±standard deviation. E wave and A wave-peak early filling (E) and atrial filling (A) velocities; IVRT-isovolumic relaxation time; Lat/sep e’-mean of lateral 
and septal peak early diastolic velocities; LAVI-left atrial volume index; MDT-deceleration time of peak E wave; MPI-myocardial performance index; s’-peak systolic annular velocity. 
*P value of paired samples test; **P value of comparison of groups in terms of after treatment values corrected for baseline values
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Discussion
The main findings of the present study are that plasma ape-
lin concentrations increased significantly in newly diagnosed 
patients with primary hypertension after 1 month of effective 
treatment with either telmisartan or amlodipine. This is the first 
study demonstrating an increase in the apelin concentration to 
a similar extent with two anti-hypertensive drug regimens with 
different mechanisms of action. The change in the apelin con-
centration was not associated with the observed improvements 
in left ventricular diastolic function as well as the decrease in 
blood pressure.
It has previously been reported that apelin may play a role in 
the pathophysiology of hypertension (4–6, 16–21). In animal mod-
els and clinical studies, decreased apelin concentrations have 
been documented in hypertension compared with participants 
with normal blood pressure (4, 5, 20, 21). Papadopoulos et al. 
(21) measured plasma apelin concentration in 130 patients who 
underwent 24-hour ambulatory blood pressure monitoring; 24 
were found to have masked hypertension. They found that apelin 
concentration was significantly lower in patients with masked 
hypertension compared with normotensive controls. In a recent 
study, even subjects with high normal blood pressure had sig-
nificantly lower apelin levels than subjects with optimal blood 
pressure (22). 
Przewlocka-Kosmala et al. (5) enrolled 232 patients with hy-
pertension, 56 of whom had never been treated. Their control 
group comprised 76 healthy volunteers, and patients with hyper-
tension were found to have lower plasma apelin concentration 
than controls. In that study apelin concentration was reported 
to be in the range of 120–480 pg/mL, which are in a similar range 
as our findings (reported as ng/mL in our study). Interestingly, 
patients with hypertension who had been taking antihyperten-
sive drugs (discontinued 2 weeks before entering the study) and 
those who had never been treated had similar plasma apelin 
concentrations, however, they also had similar SBP and DBP (in 
the entire cohort, mean SBP was 155±13 mm Hg and the mean 
DBP was 94±10 mm Hg). The finding that the comparably low 
plasma apelin concentrations in treatment naive patients with 
hypertension and those who had discontinued antihypertensive 
treatment had in the study by Przewlocka-Kosmala et al.(5), in-
formed our decision to examine the change in apelin concentra-
tion in patients newly diagnosed with hypertension after being 
established on an effective treatment regime, as well as to com-
pare the baseline plasma apelin concentration of patients with 
healthy controls. In our cohort, treatment brought about a sig-
nificant decrease in blood pressure and a significant increase 
in plasma apelin concentration; however, there was no correla-
tion between the magnitudes of these changes. These findings 
are in agreement with Przewlocka-Kosmala et al. (5), who also 
found no significant correlation between the extent of reduction 
in circulating apelin concentration and blood pressure in 232 pa-
tients with essential hypertension. They suggested that ambula-
tory blood pressure monitoring might be a more accurate tech-
nique to illuminate a possible association; we used ambulatory 
blood pressure monitoring to evaluate the efficiency of therapy 1 
month after the initiation of treatment, but made the diagnosis of 
hypertension on the basis of recordings taken in our outpatients 
department. Most of the patients in our cohort had stage 1 hy-
pertension requiring monotherapy, and patients requiring com-
bination therapy were excluded from the study. The lack of a sta-
tistically significant relationship between the change in plasma 
apelin concentration and the change in blood pressure concurs 
with other investigations but might also be explained by our diag-
nostic methods, the lack of a wide variation in blood pressure in 
the treatment groups, and a relatively small sample size.
Apelin is thought to act centrally and peripherally to reduce 
blood pressure. In the peripheries, apelin causes arterial vaso-
dilatation via the endothelial nitric oxide pathway (19, 23, 24); 
however, it has no effect on venous tone (25). An increase in in-
tracerebral apelin causes a hypertensive response (23, 24); thus 
it appears that the central and peripheral components of the ape-
linergic system seem to have opposing effects on arterial blood 
pressure. It is difficult to explain the mechanism by which plasma 
apelin concentration might increase after control over blood 
pressure has been restored, as the activity and pharmacology 
Table 5. Correlation of proportional change in apelin concentration 
and proportional change in echocardiographic parameters and blood 
pressure after 1 month of therapy
n=77 Correlation coefficient
  r P
E wave  0.094 0.416
A wave 0.163 0.157
E/A  0.065 0.572
MDT 0.056 0.629
IVRT 0.027 0.813
LAVI 0.011 0.923
Lat-sep e’ -0.033 0.778
Lateral IVRT 0.117 0.456
Septal IVRT 0.059 0.349
Lateral s’ -0.078 0.292
Septal s’ -0.014 0.543
E/e’ 0.032 0.781
Lateral MPI -0.233 0.041
Septal MPI -0.098 0.395
SBP 0.073 0.526
DBP 0.075 0.516
Data obtained from Spearman’s correlation analysis are shown in the table. A wave-
peak atrial filling (A) velocity; DBP - diastolic blood pressure; E wave - peak early filling 
velocity; IVRT - isovolumic relaxation time; Lat/sep e’ - mean of lateral and septal peak 
early diastolic velocities; LAVI - left atrial volume index; MDT - deceleration time of E 
wave; MPI - myocardial performance index; s’ - peak systolic annular velocity; SBP - 
systolic blood pressure
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of the apelin/APJ pathway is not fully understood; our study was 
not designed to identify the underlying mechanism. It has been 
reported that apelin opposes angiotensin in the cardiovascular 
system, and that angiotensin converting enzyme 2 (ACE 2) acts to 
eliminate apelin (26). In experimental animals, lack of activity in 
the APJ pathway reportedly suppressed expression of the angio-
tensin II type 1 receptor, which increased when APJ was activat-
ed (27). In a rat model of hypertensive heart failure, down regula-
tion of apelin and APJ expression was significantly increased in 
animals treated with olmesartan (28). These observations sup-
port our findings that plasma apelin concentration is elevated 
in patients treated with telmisartan; nonetheless amlodipine 
treatment elevated circulating apelin concentration to a simi-
lar extent. It is plausible; therefore, that any increase in plasma 
apelin concentration occurs through one or more mechanisms 
triggered by reduction in blood pressure, and are independent of 
the drug used. Further studies are needed to test this hypothesis.
We observed that diastolic function had improved after 1 
month of therapy with telmisartan or amlodipine, and that the 
magnitude of the improvement with each drug was comparable. 
Zaliunas et al. (29) have also reported a measurable benefit of 
amlodipine on LV diastolic function in patients with arterial hy-
pertension and stable angina after 4 weeks of treatment. In the 
longer term, Mattioli et al. (30) observed significant improve-
ments in diastolic filling parameters, LA volume and LV hyper-
trophy after 3, 6, 9, and 12 months of telmisartan monotherapy. 
We used these findings to inform our decision that 1 month of 
treatment was enough to control hypertension, and for improve-
ment in diastolic function and changes apelin concentration to 
be evident. Lower levels of apelin is reportedly independently as-
sociated with more profound impairment of LV diastolic function 
(5), but despite the beneficial effects of treatment on diastolic 
function and apelin concentration, we did not find any associa-
tion between the change in circulating apelin concentration and 
indices of diastolic function. The pathophysiological mechanism 
underpinning the relationship between apelin and diastolic func-
tion is not understood. Przewlocka-Kosmala et al. (5) suggested 
that the deleterious effect of decreased apelin concentration on 
LV diastolic function could be a consequence of diminished en-
dothelial nitric oxide synthesis; however, further studies will be 
needed to examine this hypothesis. The absence of a relation-
ship between follow-up apelin concentration and improvement 
in diastolic function in our cohort may be due to the relatively 
short duration of our study.
Study limitations
Our study has several limitations. First, our study sample size 
might not have been large enough to detect significant associa-
tions between change in apelin concentration and the echocar-
diographic parameters used to determine LV diastolic function. 
Second, using clinic measurements to diagnose hypertension 
may have influenced the composition of the study cohort, al-
though we used ambulatory monitoring to measure blood pres-
sure at the end of the treatment period, and the protocol was 
the same for all participants. Third, the study design was open 
label. Fourth, 13 patients were excluded from the analysis for 
a variety of reasons, and although this is a relatively high pro-
portion of the study cohort, exclusions were evenly distributed 
between the groups. We did not use more sensitive echocardio-
graphic methods of evaluating cardiac function, such as myo-
cardial strain and strain rate. These methods are able to detect 
subtle changes in myocardial mechanics and a relationship with 
change in apelin concentration could have been observed; how-
ever, we elected to use well-established parameters to evaluate 
LV diastolic function recommended in international guidelines. 
Finally, even though we were able to show significant differenc-
es in apelin concentration, blood pressure measurements, and 
echocardiographic indices for diastolic function, relatively short 
study period is another limitation and longer duration follow-up 
studies may strengthen the accuracy of data.
Conclusions
Plasma apelin concentration was significantly lower in pa-
tients with hypertension than the control group, who had normal 
blood pressure. A significant increase in apelin concentration 
was observed after 1 month of effective treatment with either 
telmisartan or amlodipine. The magnitude of the change in apelin 
concentration was associated neither with the extent of the im-
provement in diastolic function nor with the degree of change in 
blood pressure. Effective blood pressure control, rather than the 
drug choice, seems to increase apelin concentration.
Acknowledgements: There is no conflict of interest regarding any 
of the authors. All support for this study came from institutional and 
departmental resources.
Funding: This research received no grant from any funding agency 
in the public, commercial, or not-for-profit sectors.
Conflict of interest: None declared.
Peer-review: Externally peer-reviewed.
Authorship contributions: Concept – B.P.; Design – B.P., K.O.; Super-
vision – B.P., K.O., U.A.B., M.Z.U., D.Ö., H.M.; Materials – B.P., K.O., U.A.B., 
M.Z.U., D.Ö., H.M.; Data collection &/or processing – B.P., K.O., U.A.B., 
M.Z.U., D.Ö., H.M.; Analysis &/or interpretation – B.P., D.Ö.; Literature 
search – B.P., K.O.; Writing – S.S.B., B.P., K.O.; Critical review – B.P., K.O.; 
Other – D.Ö.
References
1. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakewaga T, Zou MX. Iso-
lation and characterization of a novel endogenous peptide ligand 
for the human APJ receptor. Biochem Biophys Res Commun 1998; 
251: 471-6. Crossref
Baysal et al.
Apelin in hypertension after treatment Anatol J Cardiol 2017; 17: 125-31130
2. Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y. Charac-
terization of apelin, the ligand for the APJ receptor. J Neurochem 
2000; 74: 34-41. Crossref
3. Barnes G, Japp AG, Newby DE. Translational promise of the apelin/
APJ system. Heart 2010; 96: 1011-6. Crossref
4. Sönmez A, Çelebi G, Erdem G, Tapan S, Genç H, Taşcı I, et al. Plasma 
apelin and ADMA levels in patients with essential hypertension. 
Clin Exp Hypertens 2010; 32: 179-83. Crossref
5. Przewlocka-Kosmala M, Kotwica T, Mysiak A, Kosmala W. Re-
duced circulating apelin in essential hypertension and its associa-
tion with cardiac dysfunction. J Hypertens 2011; 29: 971-9. Crossref
6. Charles CJ. Putative role for apelin in pressure/volume homeosta-
sis and cardiovascular disease. Cardiovasc Hematol Agents Med 
Chem 2007; 5: 1-10. Crossref
7. Mancia G, Fagard R, Narkiewicz K, Redán J, Zanchetti A, Böhm 
M, et al. 2013 Practice guidelines for the management of arterial 
hypertension: the Task Force for the Management of Arterial Hy-
pertension of the European Society of Hypertension (ESH) and of 
the European Society of Cardiology (ESC). J Hypertens 2013; 34: 
1925-38. Crossref
8. Zhou Y, Wang Y, Qiao S. Apelin: a potential marker of coronary ar-
tery stenosis and atherosclerotic plaque stability in ACS patients. 
Int Heart J 2014; 55: 204-12. Crossref
9. Cebeci AN, Güven A, Kuru LI. Perinephric adipose tissue thickness 
in relation to blood pressure, plasma apelin and C -reactive protein 
levels in obese adolescents. Minerva Endocrinol 2016; 41: 166-74.
10. Habchi M, Duvillard L, Cottet V, Brindisi MC, Bouillet B, Beacco M, 
et al. Circulating apelin is increased in patients with type 1 or type 
2 diabetes and is associated with better glycaemic control. Clin En-
docrinol (Oxf) 2014; 81: 696-701. Crossref
11. Peltonen T, Näpänkangas J, Vuolteenaho O, Ohtonen P, Soini Y, Ju-
vonen T, et al. Apelin and its receptor APJ in human aortic valve 
stenosis. J Heart Valve Dis 2009; 18: 644-52.
12. Zhang DL, Liao H, Wei YY, Zhang Y, Zhang QD, Wang ZG. Elevation of 
serum apelin-13 is positively correlated with ADMA in patients on 
maintenance hemodialysis. Clin Nephrol 2009; 71: 405-12. Crossref
13. Dalzell JR, Rocchiccioli JP, Weir RA, Jackson CE, Padmanabhan N, 
Gardner RS, et al. The Emerging Potential of the Apelin-APJ System 
in Heart Failure. J Card Fail 2015; 21: 489-98. Crossref
14. Chapman CB, Ewer SM, Kelly AF, Jacobson KM, Leal MA, Rahko PS. 
Classification of left ventricular diastolic function using American 
Society of Echocardiography Guidelines: agreement among echo-
cardiographers. Echocardiography 2013; 30: 1022-31. Crossref
15. Tei C, Nishimura RA, Seward JB, Tajik AJ. Noninvasive Doppler-
derived myocardial performance index: correlation with simulta-
neous measurements of cardiac catheterization measurements J 
Am Soc Echocardiogr 1997; 10: 169-78. Crossref
16. Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Fujimiya M. 
The novel peptide apelin lowers blood pressure via nitric oxide-
dependent mechanism. Regul Pept 2001; 99: 87-92. Crossref
17. Lee DK, Saldivia VR, Nguyen T, Cheng R, George SR, O’Dowd BF. 
Modification of the terminal residue of apelin-13 antagonizes its 
hypotensive action. Endocrinology 2005; 146: 231-6. Crossref
18. Ishida J, Hashimoto T, Hashimoto Y, Nishiwaki S, Iguchi T, Harada 
S. Regulatory roles for APJ, a seven-transmembrane receptor re-
lated to angiotensin-type 1 receptor in blood pressure in vivo. J Biol 
Chem 2004; 279: 26274-9. Crossref
19. Kagiyama S, Fukuhara M, Matsumura K, Lin Y, Fujii K, Iida M. Cen-
tral and peripheral cardiovascular actions of apelin in conscious 
rats. Regul Pept 2005; 125: 55-9. Crossref
20. Zhang J, Ren CX, Qi YF, Lou LX, Chen L, Zhang LK, et al. Exercise 
training promotes expression of apelin and APJ of cardiovascular 
tissues in spontaneously hypertensive rats. Life Sci 2006; 79: 1153-
9. Crossref
21. Papadopoulos DP, Mourouzis I, Faselis C, Perrea D, Makris T, Tsiou-
fis C. Masked hypertension and atherogenesis: the impact of apelin 
and relaxin plasma levels. J Clin Hypertens (Greenwich) 2013; 15: 
333-6. Crossref
22.  Liakos CI, Sanidas EA, Perrea DN, Grassos CA, Chantziara V, Viniou 
NA, et al. Apelin and visfatin plasma levels in healthy individuals 
with high normal blood pressure. Am J Hypertens 2016; 29: 549-52.
23. Seyedabadi M, Goodchild AK, Pilowsky PM. Site-specific effects 
of apelin-13 in the rat medulla oblongata on arterial pressure and 
respiration. Auton Neurosci 2002; 101: 32-8. Crossref
24. Zhang Q, Yao F, Raizada MK, O’Rourke ST, Sun C. Apelin gene trans-
fer into the rostral ventrolateral medulla induces chronic blood 
pressure elevation in normotensive rats. Circ Res 2009; 104: 1421-8.
25. Japp AG, Cruden NL, Amer DA, Li VK, Goudie EB, Johnston NR, et 
al. Vascular effects of apelin in vivo in man. J Am Coll Cardiol 2008; 
52: 908-13. Crossref
26. Iwanaga Y, Kihara Y, Takenaka H, Kita T. Down-regulation of cardiac 
apelin system in hypertrophied and failing hearts: possible role of 
angiotensin II-angiotensin type 1 receptor system. J Mol Cell Car-
diol 2006; 41: 798-806. Crossref
27. Sun X, Iida S, Yoshikawa A, Senbonmatsu R, Imanaka K, Maruyama 
K, et al. Non-activated APJ suppresses the angiotensin II type 1 re-
ceptor, whereas apelin-activated APJ acts conversely. Hypertens 
Res 2011; 34: 701-6. Crossref
28. Fukushima H, Kobayashi N, Takeshima H, Koguchi W, Ishimitsu T. 
Effects of olmesartan on Apelin/APJ and Akt/endothelial nitric ox-
ide synthase pathway in Dahl rats with end-stage heart failure. J 
Cardiovasc Pharmacol 2010; 55: 83-8. Crossref
29. Zaliunas R, Jurkevicus R, Zabiela V, Brazdzionyte J. Effect of am-
lodipine and lacidipine on left ventricular diastolic and long axis 
functions in arterial hypertension and stable angina pectoris. Acta 
Cardiol 2005; 60: 239-46. Crossref
30. Mattioli A, Zennaro M, Bonatti S, Bonetti L, Mattioli G. Regression 
of left ventricular hypertrophy and improvement of diastolic func-
tion in hypertensive patients treated with telmisartan. Int J Cardiol 
2004; 97: 383-8. Crossref
Baysal et al.
Apelin in hypertension after treatmentAnatol J Cardiol 2017; 17: 125-31 131
